Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Longitudinal effects of SARS-CoV-2 breakthrough infection on imprinting of neutralizing antibody responses.
Einhauser S, Asam C, Weps M, Senninger A, Peterhoff D, Bauernfeind S, Asbach B, Carnell GW, Heeney JL, Wytopil M, Fuchs A, Messmann H, Prelog M, Liese J, Jeske SD, Protzer U, Hoelscher M, Geldmacher C, Überla K, Steininger P, Wagner R; CoVaKo Study group. Einhauser S, et al. EBioMedicine. 2024 Nov 9;110:105438. doi: 10.1016/j.ebiom.2024.105438. Online ahead of print. EBioMedicine. 2024. PMID: 39522353 Free article.
Hybrid immunity by two COVID-19 mRNA vaccinations and one breakthrough infection provides a robust and balanced cellular immune response as basic immunity against severe acute respiratory syndrome coronavirus 2.
Almanzar G, Koosha K, Vogt T, Stein A, Ziegler L, Asam C, Weps M, Schwägerl V, Richter L, Hepp N, Fuchs A, Wagenhäuser I, Reusch J, Krone M, Geldmacher C, Protzer U, Steininger P, Überla K, Wagner R, Liese J, Prelog M. Almanzar G, et al. Among authors: schwagerl v. J Med Virol. 2024 Jun;96(6):e29739. doi: 10.1002/jmv.29739. J Med Virol. 2024. PMID: 38899449
Clinical and immunological benefits of full primary COVID-19 vaccination in individuals with SARS-CoV-2 breakthrough infections: A prospective cohort study in non-hospitalized adults.
Prelog M, Jeske SD, Asam C, Fuchs A, Wieser A, Gall C, Wytopil M, Mueller-Schmucker SM, Beileke S, Goekkaya M, Kling E, Geldmacher C, Rubio-Acero R, Plank M, Christa C, Willmann A, Vu M, Einhauser S, Weps M, Lampl BMJ, Almanzar G, Kousha K, Schwägerl V, Liebl B, Weber B, Drescher J, Scheidt J, Gefeller O, Messmann H, Protzer U, Liese J, Hoelscher M, Wagner R, Überla K, Steininger P; CoVaKo Study Group. Prelog M, et al. Among authors: schwagerl v. J Clin Virol. 2024 Feb;170:105622. doi: 10.1016/j.jcv.2023.105622. Epub 2023 Nov 28. J Clin Virol. 2024. PMID: 38091664